Prospects for an SV40 vaccine

Authors: Imperiale M.J.^{1, 2, 3}; Pass H.I.⁵; Sanda M.G.^{1, 3, 4}

Source: Seminars in Cancer Biology, Volume 11, Number 1, February 2001 , pp. 81-85(5)

Buy & download fulltext article:

Price: $52.63 plus tax (Refund Policy)

Abstract:

The identification of SV40 as a possible cause of human cancer leads to the question of whether the unique properties of the virus can be exploited to treat patients with SV40-positive mesotheliomas, which are otherwise refractory to successful intervention. A modified SV40 T antigen, from which the transforming domains have been removed, has been cloned into a vaccinia virus vector and tested in animal tumor model systems. It has been shown to be effective against both subsequent tumor challenge and pre-existing tumors. Thus, the potential exists for use of such a vaccine in mesothelioma patients. Copyright 2001 Academic Press

Language: English

Document Type: Research article

Affiliations: 1: Department of Microbiology and Immunology 2: Comprehensive Cancer Center 3: Center for Gene Therapy 4: Department of Surgery, University of Michigan Medical School, 1500 E. Medical Center Dr., 6310 Cancer Center, Ann Arbor, MI 48109-0942, USA 5: Karmanos Cancer Center, Wayne State University School of Medicine, USA

Publication date: 2001-02-01